Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer

• Published in: JNCI : Journal of the National Cancer Institute 2015-03, Vol.107 (3), p.1
• Main Authors: Nyante, Sarah J, Sherman, Mark E, Pfeiffer, Ruth M, Berrington de Gonzalez, Amy, Brinton, Louise A, Aiello Bowles, Erin J, Hoover, Robert N, Glass, Andrew, Gierach, Gretchen L
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents, Hormonal - administration & dosage; Breast cancer; Breast Neoplasms - chemistry; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Case-Control Studies; Clinical trials; Endocrine therapy; Female; Humans; Mammography; Menopause; Middle Aged; Northwestern United States; Oncology; Premenopause; Prognosis; Receptors, Estrogen - analysis; Selective Estrogen Receptor Modulators - administration & dosage; Survival analysis; Tamoxifen - administration & dosage
• ISSN: 0027-8874; 1460-2105
• DOI: 10.1093/jnci/dju425

A prior analysis of postmenopausal breast cancer patients linked a decline in mammographic density (MD) following the initiation of tamoxifen treatment with improved survival, but excluded premenopausal women, for whom tamoxifen is the primary anti-endocrine therapy. Therefore, we evaluated change in MD after tamoxifen and breast cancer death among patients age 32 to 87 years. This case-control study included 349 estrogen receptor (ER)-positive breast cancer patients who were treated with tamoxifen at Kaiser Permanente Northwest (1990-2008): 97 who died from breast cancer (case patients) and 252 who did not (control patients), matched on age and year at diagnosis and disease stage. Percent MD in the unaffected breast was measured at baseline (mean six months before tamoxifen initiation) and follow-up (mean 12 months after initiation). Associations between change in MD and breast cancer death were estimated using conditional logistic regression. Patients in the highest tertile of MD decline had a lower risk of breast cancer death when compared with women in the lowest tertile (odds ratio [OR] = 0.44, 95% confidence interval [CI] = 0.22 to 0.88); results were similar after adjustment for baseline MD (OR = 0.49, 95% CI = 0.23 to 1.02). Reductions in death were observed only among patients in the middle and upper tertiles of baseline MD. Associations did not differ by age, tamoxifen use duration, estrogen and/or progestin use, body mass index, or receipt of chemotherapy or radiotherapy. These data suggest that younger and older ER-positive breast cancer patients who experience large reductions in MD following tamoxifen initiation have an improved prognosis.